MX2011008289A - Tabletas para terapia combinada. - Google Patents
Tabletas para terapia combinada.Info
- Publication number
- MX2011008289A MX2011008289A MX2011008289A MX2011008289A MX2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A
- Authority
- MX
- Mexico
- Prior art keywords
- tablets
- formula
- combination therapy
- compound
- iii
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona formas de dosis sólidas (por ejemplo, tabletas) que comprenden un compuesto de la Fórmula I, un compuesto de la Fórmula II, un compuesto de la Fórmula III y una sal de la Fórmula IV. [inserto Fórmula I II, III, IV].
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15065509P | 2009-02-06 | 2009-02-06 | |
| US15065209P | 2009-02-06 | 2009-02-06 | |
| PCT/US2010/023226 WO2010091197A2 (en) | 2009-02-06 | 2010-02-04 | Tablets for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008289A true MX2011008289A (es) | 2011-09-15 |
Family
ID=41722740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008289A MX2011008289A (es) | 2009-02-06 | 2010-02-04 | Tabletas para terapia combinada. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20100285122A1 (es) |
| EP (1) | EP2393485B1 (es) |
| JP (2) | JP5611242B2 (es) |
| KR (2) | KR101738325B1 (es) |
| CN (1) | CN102307573B (es) |
| AP (1) | AP3250A (es) |
| AR (1) | AR075369A1 (es) |
| AU (1) | AU2010210598B2 (es) |
| BR (1) | BRPI1008664A2 (es) |
| CA (1) | CA2750521A1 (es) |
| CL (1) | CL2011001885A1 (es) |
| CY (1) | CY1116852T1 (es) |
| DK (1) | DK2393485T3 (es) |
| EA (2) | EA021313B1 (es) |
| EC (1) | ECSP11011307A (es) |
| ES (1) | ES2548886T3 (es) |
| HR (1) | HRP20151009T1 (es) |
| HU (1) | HUE025822T2 (es) |
| IL (1) | IL214227A (es) |
| MX (1) | MX2011008289A (es) |
| NZ (1) | NZ594214A (es) |
| PE (1) | PE20110994A1 (es) |
| PL (1) | PL2393485T3 (es) |
| PT (1) | PT2393485E (es) |
| SG (3) | SG10201706215UA (es) |
| SI (1) | SI2393485T1 (es) |
| SM (1) | SMT201500266B (es) |
| TW (1) | TWI444367B (es) |
| UY (1) | UY32424A (es) |
| WO (1) | WO2010091197A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3112355B1 (en) | 2006-07-07 | 2020-04-29 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| DK2487166T3 (en) * | 2007-02-23 | 2017-02-20 | Gilead Sciences Inc | Modulators of the pharmacokinetic properties of therapeutics |
| ES2553897T3 (es) | 2008-05-02 | 2015-12-14 | Gilead Sciences, Inc. | El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico |
| AR084500A1 (es) | 2010-11-19 | 2013-05-22 | Gilead Sciences Inc | Tableta multicapa para tratar la infeccion por hiv en un humano |
| EP2646005B1 (en) * | 2010-11-29 | 2019-06-26 | Formac Pharmaceuticals N.v. | Compressed formulations of ordered mesoporous silicas |
| JP6122427B2 (ja) * | 2011-07-07 | 2017-04-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ダルナビル複合製剤 |
| IN2014DN01012A (es) | 2011-08-16 | 2015-05-15 | Gilead Sciences Inc | |
| WO2013115916A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| BR112014018918A8 (pt) * | 2012-02-03 | 2017-07-11 | Gilead Sciences Inc | Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais |
| EP2819644A1 (en) * | 2012-03-01 | 2015-01-07 | Gilead Sciences, Inc. | Spray dried formulations |
| CN103830192A (zh) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 |
| AP2015008510A0 (en) | 2012-12-21 | 2015-06-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| SI3607939T1 (sl) | 2015-06-30 | 2022-10-28 | Gilead Sciences, Inc. | Farmacevtske formulacije, ki obsegajo tenofovir in emtricitabin |
| SG11201802983TA (en) | 2015-11-09 | 2018-05-30 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
| ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
| WO2022034232A1 (en) * | 2020-08-13 | 2022-02-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Gastro-resistant high-strength formulation containing posaconazole |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
| JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| EP3406596A1 (en) | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| DE602006015721D1 (de) * | 2005-12-14 | 2010-09-02 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| EP3112355B1 (en) * | 2006-07-07 | 2020-04-29 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| DK2487166T3 (en) * | 2007-02-23 | 2017-02-20 | Gilead Sciences Inc | Modulators of the pharmacokinetic properties of therapeutics |
-
2010
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/en active
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Expired - Fee Related
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko not_active Expired - Fee Related
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en not_active Ceased
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
-
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
-
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008289A (es) | Tabletas para terapia combinada. | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| TN2011000291A1 (en) | Purine compounds | |
| PH12014500215B1 (en) | Notch pathway signaling inhibitor compound | |
| MX2013011330A (es) | Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso. | |
| MX2009011211A (es) | Indoles sustituidos en la posicion 7 inhibidores de mci-1. | |
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| PH12012500894A1 (en) | Benzodiazepine bromodomain inhibitor | |
| MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
| MY160392A (en) | Triptolide prodrugs | |
| MY187718A (en) | Pharmaceutical formulations | |
| MX2012004780A (es) | Inhibidores de akt. | |
| UA107476C2 (uk) | Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
| MX2010001303A (es) | Compuestos terapeuticos. | |
| PH12013500210A1 (en) | Highly crystalline valsartan | |
| JO2979B1 (en) | Cyclopropyl compounds | |
| UA103224C2 (ru) | Таблетки для комбинированной терапии | |
| SG178938A1 (en) | Therapeutic agent for chronic pain | |
| UA105675C2 (uk) | Бензодіазепіновий інгібітор бромодомену | |
| MX2013006185A (es) | Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos. | |
| UA110609C2 (uk) | Сполуки для інгібування ферменту протеасоми | |
| UA45737U (ru) | ЦИКЛОПЕНТИЛИДЕН-ГИДРАЗИД α-ПИРИДИНКАРБОНОВОЙ КИСЛОТЫ, ВЫЯВЛЯЮЩИЙ ПротивотуберкулезнУЮ АКТИВНОСТЬ | |
| UA35938U (en) | 1-phenyl-o-tolylamino-1,5-dihydropyrrol-2-one having antioxidant activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |